Lower Urinary Tract Symptoms After Intravesical Therapy
NCT ID: NCT05844059
Last Updated: 2023-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
60 participants
OBSERVATIONAL
2023-04-21
2026-04-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma
NCT05979909
Intravesical BCG: is the Urinary Bladder Ready to Receive it
NCT05335512
Intravesical Thermochemotherapy With Mitomycin-c
NCT03694535
Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients
NCT07231809
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
NCT02311101
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients undergoing instillation therapy with BCG
All patients that undergo therapy with BCG after diagnosis of non-muscle-invasive bladder cancer
Validated questionnaires
BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS
Patients undergoing instillation therapy with Mitomycin C
All patients that undergo therapy with Mitomycin C after diagnosis of non-muscle-invasive bladder cancer
Validated questionnaires
BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Validated questionnaires
BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Complete resection of the tumor
* No intravesical chemotherapy in the last 3 months
Exclusion Criteria
* Patients who are not willing to participate
* Patients with contraindications for instillation therapy (allergic reactions, immunosuppression)
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ludwig-Maximilians - University of Munich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Benedikt Ebner
Dr. med.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nikolaos Pyrgidis
Munich, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-0226
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.